Regulatory T cells in ovarian cancer: biology and therapeutic potential. - Wikidata - wikimedia - TriplyDB

Regulatory T cells in ovarian cancer: biology and therapeutic potential.

Regulatory T cells in ovarian cancer: biology and therapeutic potential.

http://www.wikidata.org/entity/Q36321305

about

Translating Treg Therapy in Humanized Mice Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer Antibody-based immunotherapy for ovarian cancer: where are we at?Sex bias in experimental immune-mediated, drug-induced liver injury in BALB/c mice: suggested roles for Tregs, estrogen, and IL-6 Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment Lymphocytes in cancer development: polarization towards pro-tumor immunity Vaccines against human carcinomas: strategies to improve antitumor immune responses.Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients.Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines.Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer.CD4+CD25hiCD127low regulatory T cells are increased in oral squamous cell carcinoma patients.Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma.Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization.Tregs and rethinking cancer immunotherapy.Epigenetic enzymes are the therapeutic targets for CD4(+)CD25(+/high)Foxp3(+) regulatory T cells Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes Immunotherapy for ovarian cancer: what's next?Tumor recognition and self-recognition induce distinct transcriptional profiles in antigen-specific CD4 T cells.Denileukin diftitox: a novel immunotoxin.Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.Past, present and future targets for immunotherapy in ovarian cancer The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.The immunomodulating roles of glycoproteins in epithelial ovarian cancer.Targeted treatment of recurrent platinum-resistant ovarian cancer: current and emerging therapies.Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination Autoimmune mediated regulation of ovarian tumor growth.Challenges and future perspectives of T cell immunotherapy in cancer Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors.Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates.B7-H6 expression correlates with cancer progression and patient's survival in human ovarian cancer.Tumor vaccines for breast cancer Predictors of immunosuppressive regulatory T lymphocytes in healthy women.Adoptive cellular therapy enhances the helper T cell response and reduces the number of regulatory T cells.Role of vaccine therapy in cancer: biology and practice Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.The tumour microenvironment and implications for cancer immunotherapy.

P2860

Q26772335-AAD4D82E-4305-42FC-A2AF-3F292A4574F5 Q26996829-9AFE0D4F-283F-414C-A8F4-FEFB31DBEE50 Q27000514-D8C8D817-440C-41C8-BB96-D0A79A35C65E Q28486040-0B76CE59-1AB2-4B5C-B8A1-551B033F7B89 Q33311571-B4AABB52-960C-41F7-B80C-57C6EB24409C Q33488520-974666D5-E931-4A29-9DE3-BB1DA7C53001 Q33671344-0170CD15-5096-4596-A560-5D5800DFF610 Q33712435-4716C289-18CC-4D9C-A7B0-628F1035A5BD Q33734281-7F2F63BA-FE48-4A08-8205-E52A010D6325 Q33754724-4F7284F0-00CC-4AA3-9C2D-6F85AAEFDEB2 Q33784707-A4CD1FD6-AE4D-48BE-8B1C-8C9819BB6481 Q33849500-998F4747-9A5A-4C91-AC77-5C61FA703C70 Q34083746-FF2525DF-776C-4357-A0AE-1A5DB7A73D3B Q34099760-75303AAF-2F64-43CF-9712-9D38B0ECE835 Q34150018-5421EE15-A4B7-488F-9EF8-3D0FA3F7C851 Q34557233-8FD6E43D-F5FA-454F-B366-A8AD20615EDE Q34625147-E5B591C1-78AC-47F0-BC43-0AB8705B6183 Q34656908-28FECFCF-79AB-4E89-A9D3-5F06AABE204A Q34664957-D30EA2A0-D6AD-407D-80D9-13F89CB76A11 Q34743514-0730BA89-7C8D-4359-84D0-CD04E999C2A0 Q34856691-F72E7D92-6E0F-479F-A3FF-6179C5E3B9CD Q35007337-9176C23F-4094-4867-BDFB-610A6535E962 Q35033249-3E1D802A-F1AE-42D5-910A-1D1BB36EEBE0 Q35034010-75BEBA6D-A451-4CE8-9D2F-84C90E897298 Q35058213-70807E0D-D93F-443B-8967-60337BF8CD82 Q35077893-870F3CC7-192D-42E0-8BA9-0BFB4D56ED10 Q35088311-17A695C8-5ECE-4A5A-BB82-A0AE0778B454 Q35451153-45647FE6-035F-4FD9-AC7B-7DE17287AC99 Q35673346-5B287676-65A3-45A7-9A64-4A1A5CF5440E Q35843507-291893C5-8955-4F19-BC3B-736C982DB557 Q36007167-88E293EC-445D-4023-904B-E3068295DFCC Q36016369-C7A6459A-4C14-4A1A-B29E-5F2FDC57B322 Q36095328-6D4D5792-4A7D-4A87-838F-E68D2BB2331E Q36204803-CE18B5FC-4904-4F7B-B0EE-CD9A75CDC180 Q36206608-48482AF1-6649-4B05-8383-6A18717E5AE7 Q36230808-09544E9C-01F5-453C-BD7C-EC70B25B31B3 Q36256420-BA000BDA-D83A-475D-A1F7-610A844C2799 Q36384598-CB5AF696-9DA0-4E43-AFDE-3ABB078C710D Q36384826-0B255851-36BA-4586-8595-F8501F90BB3F Q36521830-9BAA4256-DBED-4909-964A-FB05896C9C53

P2860

Regulatory T cells in ovarian cancer: biology and therapeutic potential.

http://www.wikidata.org/entity/Q36321305

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Regulatory T cells in ovarian cancer: biology and therapeutic potential.

@ast

Regulatory T cells in ovarian cancer: biology and therapeutic potential.

@en

type

label

Regulatory T cells in ovarian cancer: biology and therapeutic potential.

@ast

Regulatory T cells in ovarian cancer: biology and therapeutic potential.

@en

prefLabel

Regulatory T cells in ovarian cancer: biology and therapeutic potential.

@ast

Regulatory T cells in ovarian cancer: biology and therapeutic potential.

@en

P1433

Q36321305-33B194CB-9CEA-4196-8F9B-68744A0C0106

P1476

Q36321305-F46EE74E-4309-4623-8579-BF62CBAA1A9B

P2093

Q36321305-0148B2FF-8EE1-4A90-A049-7D7D051E63D0

Q36321305-04DF6A81-7FD8-4AFF-AE2F-41D9283D406B

Q36321305-281D4DDF-85F9-4AC4-B65C-83CEF818FB06

Q36321305-C13CA723-6D85-4BE5-8101-E3ED00137056

Q36321305-D543A004-67BF-421B-9E0D-32EF17803667

P2860

Q36321305-02C224A6-94C4-4886-850D-B4F62DDBDBC5

Q36321305-084650DB-E77E-4DCE-9910-2E8004484CBD

Q36321305-0BC29E43-D4FA-4752-B0A9-1388BC67D5A1

Q36321305-11FBCA78-5D05-4E59-A797-6CFF4635D65F

Q36321305-20F6497A-6F9D-4335-8523-A5302C17EDEA

Q36321305-21F1E877-BD93-4A3F-B904-9AAFCCAFB408

Q36321305-25EC70AB-B5F4-430A-856A-5CE90AE59BB0

Q36321305-25F2CC82-2A91-498D-8706-164C283BC130

Q36321305-27634AE6-33DC-4582-ABD7-027E969651DD

Q36321305-2E1CFF2A-0D26-449C-AB52-2F231C1458C0

P304

Q36321305-23AFAFF4-8AE4-460F-8FD2-0BAA93101037

P31

Q36321305-15C7150C-1199-4D0B-A55A-2333509AAFC7

P356

Q36321305-F59135BA-34EA-49B3-B328-CE95912AE948

P433

Q36321305-8678325C-E9AD-48BE-87FF-8F5C9859CA1D

P478

Q36321305-E33F26AF-EF41-45B4-AF7D-FEB9F087C146

P577

Q36321305-F9C7076E-569C-4BD5-ABFE-7F61960CBBEF

P5875

Q36321305-D03F42C2-825F-407C-92A3-EA067B1AEE5E

P698

Q36321305-F8FA4F62-C8BB-4B40-B0EC-9E944D77E9CE

P921

Q36321305-48698BCB-2E08-485E-A2D7-84A8ED71CFF6

P356

J.1600-0897.2005.00330.X

P1433

American Journal of Reproductive Immunology

P1476

Regulatory T cells in ovarian cancer: biology and therapeutic potential.

@en

P2093

Brian Barnett

http://www.w3.org/2001/XMLSchema#string

Ilona Kryczek

http://www.w3.org/2001/XMLSchema#string

Pui Cheng

http://www.w3.org/2001/XMLSchema#string

Tyler J Curiel

http://www.w3.org/2001/XMLSchema#string

Weiping Zou

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

Immunobiology of dendritic cells

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Immunosuppressive networks in the tumour environment and their therapeutic relevance

Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.

Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma.

Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells.

Cutting edge: depletion of CD4+CD25+ regulatory T cells is necessary, but not sufficient, for induction of organ-specific autoimmune disease.

Differentiation of T regulatory cells by immature dendritic cells.

P304

369-377

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1600-0897.2005.00330.X

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2005-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7462513

http://www.w3.org/2001/XMLSchema#string

P698

16305662

http://www.w3.org/2001/XMLSchema#string

P921